Topic: rheumatoid arthritis
To set its rheumatoid arthritis candidate filgotinib apart from numerous rivals, Gilead has three priorities in mind for the launch.
Humira's best days may be past, but AbbVie could one day see $20 billion in combined sales for follow-ups Rinvoq and Skyrizi, CEO Rick Gonzalez said.
We may be focusing on our forecasts for the year ahead with today's issue, but here's some Friday news we thought you shouldn't miss.
AbbVie hopes its Allergan takeover will help it weather the storm of an aging Humira. Could the next-gen antipsychotic Vraylar be a solution?
Amgen signed a deal with PBM Abarca that ties reimbursement for its RA blockbuster Enbrel to patients' willingness to stick with the drug.
Despite lagging behind in sales, RA newcomer Rinvoq is becoming a darling among physicians—and an "AbbVie halo" could be driving those warm feelings.
ICER is still concerned about high prices of next-generation RA drugs—a stance that's not going over well among RA drugmakers and patient groups.
With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.
Painted as the follow-up drug to Humira, AbbVie’s JAK med Rinvoq has blockbuster hopes in mind. An early nod in the EU could help it reach that goal.
ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.